

DAFTAR PUSTAKA

- Ayed, Houda Ben, et al. APRI score as a predictor of significant liver fibrosis in chronic hepatitis B. In: *Open Forum Infectious Diseases*. 2017. p. S196.
- Berumen, J., Baglieri, J., Kisseleva, T., & Mekeel, K. (2021). Liver fibrosis: Pathophysiology and clinical implications. *WIREs mechanisms of disease*, 13(1), e1499.
- Catanzaro, R., Aleo, A., Sciuto, M., Zanolli, L., Balakrishnan, B., & Marotta, F. (2021). FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: a monocentric retrospective study. *Clinical and Experimental Hepatology*, 7(1), 111-116.
- Çelik, D., Tatar, B., Köse, Ş., & Ödemiş, İ. (2020). Evaluation of the diagnostic validity of noninvasive tests for predicting liver fibrosis stage in chronic hepatitis B patients. *Acta Gastro-Ent Belg*, 83, 419-425.
- Chen, S., Huang, H., & Huang, W. (2021). A noninvasive model to predict liver histology for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase < 2 upper limit of normal. *BMC gastroenterology*, 21(1), 4.
- Chen, Yaqiong, et al. A novel prediction model for significant liver fibrosis in patients with chronic hepatitis b. *BioMed Research International*, 2020, 2020.1: 6839137.
- Cheng, C. H., Chu, C. Y., Chen, H. L., Lin, I. T., Wu, C. H., Lee, Y. K., ... & Bair, M. J. (2020). Subgroup analysis of the predictive ability of aspartate

aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C. *Journal of Microbiology, Immunology and Infection*, 53(4), 542-549.

Croagh, C. M., & Lubel, J. S. (2014). Natural history of chronic hepatitis B: phases in a complex relationship. *World journal of gastroenterology*, 20(30), 10395.

Darmadi, et al. Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate. *F1000Research*, 2023, 11: 1521.

Ekin, N., Uçmak, F., Ebik, B., Tuncel, E., Kaçmaz, H., Arpa, M., & Atay, A. (2022). GPR, King's Score and S-Index are superior to other non-invasive fibrosis markers in predicting the liver fibrosis in chronic Hepatitis B patients. *Acta Gastro-Enterologica Belgica*, 85(1).

Erkurt, M. A., Kaya, E., Berber, I., Koroglu, M., & Kuku, I. (2011). Thrombocytopenia in Adults: A Review. *Journal of Hematology*, 1(2-3), 44-53.

Farahmadilah, R., Rahayu, M. S., & Zubir, Z. (2022). Gambaran derajat fibrosis hati berdasarkan APRI Score dan FIB-4 Score pada pasien hepatitis B. *Jurnal Kedokteran Syiah Kuala*, 22(3).

Feitelson, M. A. (2018). Pathogenesis of Hepatitis B Virus Associated Chronic Liver Disease. *In Liver Cancer. IntechOpen*.

George, J. N., Nester, C. M., & McCrae, K. R. (2013). *Thrombocytopenia due to vascular and endothelial disorders. Hematology/Oncology Clinics of North America*, 27(3), 655–676.

Gupta, S., & Walker, S. (2021). Testing for cirrhosis. *Australian Prescriber*, 44(6), 197.

Hajar, Siti, et al. *Skor APRI pada Fibrosis hati yang Dibandingkan dengan Fibroscan*. 2012. PhD Thesis. Universitas Sumatera Utara.

Iannacone, M., & Guidotti, L. G. (2022). Immunobiology and pathogenesis of hepatitis B virus infection. *Nature Reviews Immunology*, 22(1), 19-32.

Kafeero, Hussein Mukasa, et al. Prevalence and predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic review and meta-analysis of epidemiological studies published from 2005 to 2020. *Archives of Public Health*, 2021, 79.1: 167.

Kearney, B. P., Flaherty, J. F., & Shah, J. (2006). *Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical Pharmacokinetics*, 45(11), 1153–1166.

KEMENKES, R. I. Kementerian Kesehatan Republik Indonesia. *Kementerian Kesehatan RI*, 2019, 1.1: 1.

KEMENKES, R. I. Kementerian Kesehatan Republik Indonesia. *Kementerian Kesehatan RI*, 2023.

- Liang, T. Jake. Hepatitis B: the virus and disease. *Hepatology*, 2009, 49.S5: S13-S21.
- Lim, J. K., Nguyen, M. H., Kim, W. R., Gish, R., Perumalswami, P., & Jacobson, I. M. (2020). Prevalence of chronic hepatitis B virus infection in the United States. *Official journal of the American College of Gastroenterology| ACG*, 115(9), 1429-1438.
- Liu, K., Qin, M., Tao, K., Liang, Z., Cai, F., Zhao, L., ... & Huang, J. (2021). Identification and external validation of the optimal FIB-4 and APRI thresholds for ruling in chronic hepatitis B related liver fibrosis in tertiary care settings. *Journal of clinical laboratory analysis*, 35(2), e23640.
- McCormick, P. A., & Murphy, K. M. (2022). *Splenomegaly and hypersplenism in chronic liver disease. Clinics in Liver Disease*, 26(1), 125–139.
- Moosavy, S. H., Eftekhar, E., Davoodian, P., Nejatizadeh, A., Shadman, M., Zare, S., & Nazarnezhad, M. A. (2023). AST ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran. *BMC gastroenterology*, 23(1), 145.
- Motola, D. L., Caravan, P., Chung, R. T., & Fuchs, B. C. (2014). Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. *Current pathobiology reports*, 2(4), 245–256

Najafi, Narges, et al. Evaluation of hepatic injury in chronic hepatitis B and C using APRI and FIB-4 indices compared to fibroscan results. *Annals of Medicine and Surgery*, 2024, 86.7: 3841-3846.

Nguyen, M. H., Wong, G., Gane, E., Kao, J. H., & Dusheiko, G. (2020). Hepatitis B virus: advances in prevention, diagnosis, and therapy. *Clinical microbiology reviews*, 33(2), 10-1128.

Okdemir, S., & Cakmak, E. (2022). A novel non-invasive score for the prediction of advanced fibrosis in patients with chronic hepatitis B. *Annals of hepatology*, 27(1), 100544.

Ren, G., Jia, K., Yin, S., Guan, Y., Cong, Q., & Zhu, Y. (2025). Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study. *Virology journal*, 22(1), 30

Rungta, S., Kumari, S., Deep, A., Verma, K., & Swaroop, S. (2021). APRI and FIB-4 performance to assess liver fibrosis against predefined Fibroscan values in chronic hepatitis C virus infection. *Journal of family medicine and primary care*, 10(11), 4082-4088.

Sapmaz, F. P., Büyükturan, G., Sakin, Y. S., Kalkan, İ. H., & Atasoy, P. (2022). How effective are APRI, FIB-4, FIB-5 scores in predicting liver fibrosis in chronic hepatitis B patients?. *Medicine*, 101(36), e30488.

Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in

patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol.*

2009 Oct;7(10):1104-12

Shi, Y., Zhang, X., Wong, T., Yan, T., Henry, L., Cheung, R., & Nguyen, M. H.

(2025). Sex differences in risk of adverse liver events in patients with cirrhosis. *JAMA Network Open*, 8(7), e2523674-e2523674.

Shim J. J. (2015). Long-term suppression of viral replication in chronic hepatitis

B: outcomes and future directions. *Gut and liver*, 9(3), 265–266.

Song, J. E., Lee, C. H., & Kim, B. S. (2019). Efficacy of long-term tenofovir

disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. *The Korean journal of internal medicine*, 34(4), 802.

Tamaki, N., Kurosaki, M., Huang, D. Q., & Loomba, R. (2022). Noninvasive

assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. *Hepatology research : the official journal of the Japan Society of Hepatology*, 52(6), 497–507.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown

RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 2018 Apr;67(4):1560-1599.

Tenggara, I. R., Lesmana, C. R., & Gani, R. A. (2017). Treatment Response

Monitoring of Chronic Hepatitis B Patients using Transient Elastography

and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI). *Acta Med Indones*, 49(3), 220-226.

Wang, L., Li, J., Yang, K., Zhang, H., Wang, Q., Lv, X., & Guan, S. (2020).

Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels. *Medicine*, 99(23), e20548.

Wang, J., Zhang, S., Zhu, C., Wu, C., & Huang, R. (2024). WHO 2024 Hepatitis

B Guidelines and Treatment-Eligible Rate Among Treatment-Naive Patients. *JAMA Network Open*, 7(9), e2435777-e2435777.

Wang, T. F., et al. (2020). *Thrombocytopenia in solid tumors: mechanisms and*

management. Oncology Reviews, 14(1), 451.

Wibowo, Bogi Pratomo, et al. Perbandingan potensi telbivudin dan tenofovir

dalam menurunkan skor aspartate transaminase to platelet ratio index (APRI) pada pasien Hepatitis B. *Majalah Kesehatan*, 2020, 7.1: 41-47.

WONG, V. W. S.; CHAN, H. L. Y.; WONG, G. L. H. Liver fibrosis progression

in patients with chronic hepatitis B: a prospective study with paired transient elastography. *Hong Kong Med J*, 2017, 23.4 Supplement 5.

World Health Organization. (2015). *Guidelines for the prevention, care and*

treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization.

World Health Organization. (2024). *Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection*. Geneva: World Health Organization.

Xie, G., Wang, X., Wei, R., Wang, J., Zhao, A., Chen, T., ... & Jia, W. (2020). Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection. *BMC medicine*, 18, 1-15.